PerkinElmer eBook - Next-Gen Sequencing - 19

Next-Gen Sequencing * What's Next for Next-Gen Sequencing?

According to Paul Schaffer, lifecycle leader, sequencing platforms, Roche
Diagnostics, each of the existing commercial sequencing platforms have
limitations that the user needs to assess prior to platform purchase, such as
the need for workflow automation, bioinformatics support, and data analysis.
Roche's recently announced collaborations and acquisitions of long-read
sequencing technologies will allow for phasing and the ability to sequence
across repetitive regions, simplifying data analysis, a current bottleneck.
The quick turnaround time of the platforms under development also allows
sequencing results to be integrated in clinical reports with results generated
by other technologies. If the sample-to-result turnaround time is less than one
week for the other technologies, then the NGS workflow needs to be completed
in the same time frame. In addition, single-molecule sequencing allows for the
detection of nucleotide base modifications, eliminates GC sequencing bias,
and streamlines workflow.
The clinical market will grow significantly from where is it today, according
to Schaffer. Not only are near-term applications driving demand, but current
NGS technologies are maturing and becoming more user friendly while costs
continue to decrease. The adoption rate in the U.S. clinical markets will depend
on the implementation of the guidelines for laboratory developed tests (LDTs)
and concerns about reimbursement and ethics.

| GENengnews.com

Roche Diagnostics' recently announced collaborations and acquisitions of longread sequencing technologies will allow for phasing and the ability to sequence
across repetitive regions, simplifying data analysis.

http://www.GENengnews.com

PerkinElmer eBook - Next-Gen Sequencing

Table of Contents for the Digital Edition of PerkinElmer eBook - Next-Gen Sequencing